A study comparing various noninvasive methods of detecting bladder cancer in urine

BJU International

Volumn 89, Issue 4, 2002, Pages 369-373

  Saad, A ^a   Hanbury, D C ^a   McNicholas, T A ^a   Boustead, G B ^a   Morgan, S ^b   Woodman, A C ^b  

^a LISTER HOSPITAL   (United Kingdom)

^b CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

Bladder tumour; Tumour markers; Urine cytology

Indexed keywords

TELOMERASE;

ACCURACY; ADULT; AGED; ARTICLE; ASSAY; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYSTOSCOPY; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TRANSITIONAL CELL CARCINOMA; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0036230855     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.01699.x     Document Type: Article

References (25)

1. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
2. Cancer statistics, 1997
3. Bladder cancer. Natural history and implications for urothelial cancer prevention
4. Superficial bladder cancer, progression and recurrence
5. Bladder cancer. Natural history, tumour markers and early detection strategies
6. Does flexible cystoscopy miss more tumours than rod-lens examination?
7. Surveillance for bladder cancer, the management of 4.8 million people
8. Decrease of early recurrence by means of 5-aminolevulinic acid-induced fluorescence endoscopy in patients with bladder cancer follow-up of randomised phase-III trial
9. Fluorescence assisted vs white light bladder tumour resection: A prospective randomised multicentre study
10. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer
11. NMP22 is a sensitive, cost effective test in patients at risk for bladder cancer
12. The role of urine cytology in the assessment of lower urinary tract symptoms
13. Complement factor H-related proteins are expressed in bladder cancers
14. A fixed site of DNA replication in eukaryotic cells
15. Altered extracellular matrices influence cellular processes and nuclear matrix organisations of overlying human bladder urothelial cells
16. Utilisation of nuclear matrix proteins for cancer diagnosis
17. Telomeres, telomerase and immortality
18. Specific association of human telomerase activity with immortal cells and cancer
19. Detecting human bladder cancer cells in voided urine samples by assaying for the presence of telomerase activity
20. Staging of cancer at genitourinary sites
21. The early detection and diagnosis of bladder cancer: A critical review of options
22. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTAstat test in the diagnosis of transitional cell carcinoma of the bladder
23. Telomerase activity in patients with transitional cell carcinoma: A preliminary study
24. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer
25. Nmp22: A sensitive, cost-effective test in patients at risk for bladder cancer